Researchers have also investigated the systemic effects of oral BPC-157, finding evidence of tissue-protective activity beyond the gastrointestinal tract in animal models
FDA approval requires an application with evidence on quality, safety, and effectiveness for a specific medical use
These findings provide mechanistic insight into how BPC-157 may potentiate growth hormone's proliferation-promoting effect and contribute to tendon repair, with implications for understanding tendinopathy and Achilles tendon injury recovery pathways
Vitaic S et al
A newer high-dose version called Wegovy HD, containing 7.2 mg of semaglutide, was approved for patients whose weight loss stalls on the standard 2.4 mg dose

Safety and Precautions Side Effect Profile Based on available research, 5-Amino-1MQ appears to have a favorable safety profile: Rodent studies have found no significant adverse effects No established human toxicity profile is currently available The most commonly reported effect is potential sleep disturbance An acclimation period may be necessary, with some subjects reporting decreased exercise tolerance with cardiovascular exercise during initial treatment Special Populations and Contraindications Due to limited safety data, the following populations should exercise caution or avoid use until more research is available: Pregnant or breastfeeding individuals Those with chronic health conditions Individuals taking medications that might interact with 5-Amino-1MQ Takeaway 5-Amino-1MQ represents a promising approach for addressing metabolic disorders through NNMT inhibition